Company intelligence / Profile preview

Zymeworks Inc.

Middletown, Delaware, United Stateszymeworks.com ↗

Ownership: Public · ZYME
Employees: ~278
Development stage: Commercial

Overview

Zymeworks’ lead asset zanidatamab (Ziihera®, zanidatamab-hrii) received FDA approval for previously-treated unresectable/metastatic HER2-positive BTC. Zanidatamab continues to be evaluated in multiple global clinical trials across several HER2-expressing cancers. Additional assets such as ZW191 and ZW171 are in early clinical development targeting solid tumors with novel mechanisms of action. The company’s pipeline leverages its proprietary platforms to address significant unmet needs in oncology and immune-mediated diseases

Therapeutic areas: OncologyImmunology
Modalities: Antibody-drug conjugates (ADCs)bispecific antibodiesmultispecific antibody therapeuticsprotein therapeutics
Industry: Biotech

Drug pipeline

17 assets

ZW171

16 more assets in the full pipeline.

Request access →

Partnerships

Jazz Pharmaceuticals – exclusive rights to develop/commercialize zanidatamab in key markets including US/EU/JapanBeiGene – exclusive rights to develop/commercialize zanidatamab in certain Asian territories including ChinaGSK – licensing/collaboration agreement on bispecific/multifunctional antibody technology/platforms

Financials

Market cap: $2.1B
Total revenue: $4.6M
Enterprise value: $2.1B

Beyond the preview

Go deeper on Zymeworks Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zymeworks Inc..

Explore the full profile